Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s00439-016-1686-2 http://scihub22266oqcxt.onion/10.1007/s00439-016-1686-2 C5002242!5002242!27272125     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Hum+Genet 2016 ; 135 (9): 1071-82 Nephropedia Template TP {{tp|p=27272125|t=2016. Genome editing and the next generation of antiviral therapy |pdf=|usr=}}{{27272125}} gab.com Text Genome editing and the next generation of antiviral therapy JO: Hum Genet http://www.kidney.de/pget.php?&tw=1&pmid=27272125 #FOAvip Engineered endonucleases such as homing endonucleases (HEs), zinc finger nucleases (ZFNs), Tal-effector nucleases (TALENS) and the RNA-guided engineered nucleases (RGENs or CRISPR/Cas9) can target specific DNA sequences for cleavage, and are proving to be valuable tools for gene editing. Recently engineered endonucleases have shown great promise as therapeutics for the treatment of genetic disease and infectious pathogens. In this review, we discuss recent efforts to use the HE, ZFN, TALEN and CRISPR/Cas9 gene-editing platforms as antiviral therapeutics. We also discuss the obstacles facing gene-editing antiviral therapeutics as they are tested in animal models of disease and transition towards human application. Twit Text FOAVip Genome editing and the next generation of antiviral therapy ????Hum Genet http://www.kidney.de/pget.php?&tw=1&pmid=27272125 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27272125 #FOAvip English Wikipedia <ref>{{Cite pmid|27272125}}</ref> Genome editing and the next generation of antiviral therapy #MMPMID27272125 Stone D; Niyonzima N; Jerome KR Hum Genet 2016[Sep]; 135 (9): 1071-82 PMID27272125show ga Engineered endonucleases such as homing endonucleases (HEs), zinc finger nucleases (ZFNs), Tal-effector nucleases (TALENS) and the RNA-guided engineered nucleases (RGENs or CRISPR/Cas9) can target specific DNA sequences for cleavage, and are proving to be valuable tools for gene editing. Recently engineered endonucleases have shown great promise as therapeutics for the treatment of genetic disease and infectious pathogens. In this review, we discuss recent efforts to use the HE, ZFN, TALEN and CRISPR/Cas9 gene-editing platforms as antiviral therapeutics. We also discuss the obstacles facing gene-editing antiviral therapeutics as they are tested in animal models of disease and transition towards human application. äGenome editing and the next generation of antiviral therapy (epmc).pdf DeepDyve Pubget Overpricing